Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin
This article was originally published in The Pink Sheet Daily
Executive Summary
Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.
You may also be interested in...
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition
Lovenox Lawsuit May Be Omen For Biosimilar Battles
Sanofi-Aventis' suit against FDA seeking to overturn its approval of generic Lovenox (enoxaparin) is a harbinger of what the agency will face once it approves follow-on biologics
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition